Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Gilead Sciences, Inc. or Teva Pharmaceutical Industries Limited because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Gilead Sciences, Inc. and Teva Pharmaceutical Industries Limited compare based on key financial metrics to determine which better meets your investment needs.

About Gilead Sciences, Inc. and Teva Pharmaceutical Industries Limited

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin’s lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington’s disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Latest Biotechnology and Gilead Sciences, Inc., Teva Pharmaceutical Industries Limited Stock News

As of September 4, 2026, Gilead Sciences, Inc. had a $187.2 billion market capitalization, compared to the Biotechnology median of $280.5 million. Gilead Sciences, Inc.’s stock is up 19.6% in 2026, up 0.3% in the previous five trading days and up 33.9% in the past year.

Currently, Gilead Sciences, Inc. does not have a price-earnings ratio. Gilead Sciences, Inc.’s trailing 12-month revenue is $30.5 billion with a -10.6% net profit margin. Year-over-year quarterly sales growth most recently was 10.2%. Analysts expect adjusted earnings to reach $-0.431 per share for the current fiscal year. Gilead Sciences, Inc. currently has a 2.2% dividend yield.

As of September 4, 2026, Teva Pharmaceutical Industries Limited had a $42.4 billion market cap, putting it in the 92nd percentile of all stocks. Teva Pharmaceutical Industries Limited’s stock is up 18% in 2026, up 2.2% in the previous five trading days and up 96.75% in the past year.

Currently, Teva Pharmaceutical Industries Limited’s price-earnings ratio is 60.4. Teva Pharmaceutical Industries Limited’s trailing 12-month revenue is $17.3 billion with a 4.1% net profit margin. Year-over-year quarterly sales growth most recently was -0.8%. Analysts expect adjusted earnings to reach $2.137 per share for the current fiscal year. Teva Pharmaceutical Industries Limited does not currently pay a dividend.

How We Compare Gilead Sciences, Inc. and Teva Pharmaceutical Industries Limited Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Gilead Sciences, Inc. and Teva Pharmaceutical Industries Limited’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Gilead Sciences, Inc. and Teva Pharmaceutical Industries Limited Stock Value Grades

Company	Ticker	Value
Gilead Sciences, Inc.	GILD	D
Teva Pharmaceutical Industries Limited	TEVA	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Gilead Sciences, Inc. has a Value Score of 28, which is Expensive. Teva Pharmaceutical Industries Limited has a Value Score of 24, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither Gilead Sciences, Inc. or Teva Pharmaceutical Industries Limited has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Gilead Sciences, Inc. or Teva Pharmaceutical Industries Limited is the better investment when it comes to value.

Gilead Sciences, Inc. and Teva Pharmaceutical Industries Limited’s Momentum Grades

Company	Ticker	Momentum
Gilead Sciences, Inc.	GILD	B
Teva Pharmaceutical Industries Limited	TEVA	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Gilead Sciences, Inc. has a Momentum Score of 72, which is Strong. Teva Pharmaceutical Industries Limited has a Momentum Score of 85, which is Very Strong.

The Momentum Grade Winner: Teva Pharmaceutical Industries Limited

As you can clearly see from the Momentum Grade breakdown above, Teva Pharmaceutical Industries Limited is considered to have stronger momentum compared to Gilead Sciences, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Teva Pharmaceutical Industries Limited could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Gilead Sciences, Inc. and Teva Pharmaceutical Industries Limited’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Gilead Sciences, Inc.	GILD	B
Teva Pharmaceutical Industries Limited	TEVA	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Gilead Sciences, Inc. has a Earnings Estimate Score of 73, which is Positive. Teva Pharmaceutical Industries Limited has a Earnings Estimate Score of 33, which is Negative.

The Earnings Estimate Revisions Grade Winner: Gilead Sciences, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Gilead Sciences, Inc. has a better Earnings Estimate Revisions Grade than Teva Pharmaceutical Industries Limited. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Gilead Sciences, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Gilead Sciences, Inc. and Teva Pharmaceutical Industries Limited Grades

In addition to Momentum, Value and Estimate Revisions, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Gilead Sciences, Inc. and Teva Pharmaceutical Industries Limited pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Gilead Sciences, Inc. or Teva Pharmaceutical Industries Limited Stock?

Overall, Gilead Sciences, Inc. stock has a Value Score of 28, Momentum Score of 72 and Estimate Revisions Score of 73.

Teva Pharmaceutical Industries Limited stock has a Value Score of 24, Momentum Score of 85 and Estimate Revisions Score of 33.

Comparing Gilead Sciences, Inc. and Teva Pharmaceutical Industries Limited’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.